Topic: Women biopharma executives
Since 2015, female representation in the C-suite has grown from 17% to 21%. But many women are held back by a “broken rung” in the corporate ladder.
More women have climbed to the top of the corporate ladder than ever before. This report recognizes 20 of them: women at the top of the life sciences field who lead the charge in everything from research to business development and regulatory effort, or have outright built and run their own companies.
Teresa Rodó, Head of Global Healthcare Operations, Merck KGaA
Dana Rodden, Digital Center of Excellence and Marketing Operations leader for the U.S., Merck & Co.
Jacki Dioguardi, Vice President of Commercial Business Technology Solutions, AbbVie
Jing Marantz, Senior Vice President, Head of Medical Affairs, Alnylam Pharmaceuticals
Jennifer Taubert, Worldwide Chairman of Pharmaceutical and Executive Vice President, Johnson & Johnson
When Lina Shields became Lilly's chief media officer, the U.S. ran the same media plan it had launched more than a decade before. That wouldn't do.
GSK has seen plenty of changes across its executive ranks over the last couple of years as CEO Emma Walmsley took the helm, but they’re still coming.
Mylan has been no stranger to controversy in recent years, and now CEO Heather Bresch plans to retire in 2020.